Podcasts about Midas

Welcome back to The Insurance Dudes! In this episode, Craig and Jason sit down with Sethe Smith, owner of the Sethe Smith Agency in Fort Wayne, Indiana, for a candid conversation packed with both wisdom and wild stories from the insurance trenches. From cleaning up unforgettable office mishaps to building a top-performing agency from scratch, Sethe shares the real-life ups and downs of agency ownership—including valuable lessons learned from failure, the importance of having a “why,” and the challenges of hiring and retaining great salespeople.Whether you're an aspiring agent, a seasoned agency owner, or just someone looking for a fresh take on what it really takes to grow a successful insurance business, this episode pulls back the curtain on the highs, the lows, and everything in between. Tune in for some laughs, plenty of actionable insights, and inspiration to tackle the daily grind with grit and vision.Join the elite ranks of P&C agents. Sign up for Agent Elite today and get exclusive resources to grow your agency!

Dr. Ben Derman of the University of Chicago Medicine joins the show to unpack major updates in multiple myeloma presented at ASCO and EHA 2025. He discusses the growing role of quadruple therapy across all patient populations and its implications for the future of autologous stem cell transplant, including insights from the MIDAS trial on MRD-guided transplant decisions. Additional highlights include MRD-negativity as a potential off-ramp for maintenance therapy, evolving data from frontline triplet vs. quadruplet studies, real-world referral trends, CARTITUDE-4 subgroup outcomes, and the expanding utility of bispecifics and trispecific antibodies, particularly for extramedullary disease. Check out Chadi's website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/ Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

Welcome back to The Insurance Dudes! In today's episode, hosts Craig Pretzinger and Jason Feltman sit down with Tung Le, the unstoppable insurance entrepreneur behind a thriving Allstate agency in Houston, Texas. Tung gets real about his rollercoaster journey, starting from scratch in March 2020—just as the world shut down. From losing his first employees on day one, to hitting the phones himself, Tung shares how he bootstrapped his way through the uncertainty of COVID, faced painful early setbacks, and relentlessly built a powerhouse $12 million book of business in just a few years.Listen in as Tung opens up about the tough lessons learned in hiring, building a resilient team, and outlasting the storms—literally and figuratively—of the Texas insurance market. He gets candid about separating service and sales teams, dialing in on valuable data and zip codes, and learning to adapt strategies as both the industry and his agency evolve. If you've ever wondered what it takes to grow an agency from zero to millions, especially through some of the most challenging years in recent memory, this episode is packed with practical insights, plenty of laughs, and straight-shooting advice you won't want to miss. Let's jump in!Join the elite ranks of P&C agents. Sign up for Agent Elite today and get exclusive resources to grow your agency!

In this episode, we dissect the phase 3 MIDAS trial in newly diagnosed transplant-eligible multiple myeloma with Dr. Meera Mohan. https://pubmed.ncbi.nlm.nih.gov/39841461/https://pubmed.ncbi.nlm.nih.gov/40459097/

Portland-based trio BELONGING have been bashing out their brand of noisy indie rock for a few years. Now part of Dipterid Records, the band is re-releasing their debut LP Hollow Cells, as well as an upcoming split with Inny.Music by:New BrutalismBelongingInnyIntro music by:Hot ZonePatreon: https://www.patreon.com/GettingitoutpodcastEmail: dan@gettingitout.netWebsite: http://gettingitout.net/Instagram: @getting_it_out_podcastFacebook: www.facebook.com/gettingitoutpodcastX: @GettingItOutPodSupport this show http://supporter.acast.com/getting-it-out. Hosted on Acast. See acast.com/privacy for more information.

Tune in to this episode of the Security Token Show where this week Herwig Konings and guest contributors, Tal Elyashiv, Managing Partner at SPiCE VC, Nico Pantelis, Partner at Blue Bay Ventures, and Jason Barraza cover the industry leading headlines and market movements, including Robinhood's tokenized stocks, stablecoin issuers like Circle and Ripple applying for bank charters, SPiCE VC's 3rd investor payout, and more RWA news!   This week Jason Barraza had a chance to sit with Yuval Rooz, Co-Founder and CEO of Digital Asset, for an inside look at their $135 million raise, the growing momentum behind Canton Network including integrating with Nasdaq Calyspo, and why privacy, composability, and real world asset tokenization as a whole are going to change global markets.  Did Yuval leave you on a cliff hanger before the RWA Foundation Updates? Jason and Yuval dive into it and more on the full interview available here: https://youtu.be/Aj4URNZo9uM    Company of the Week - Herwig: Robinhood   Companies in the news include SPiCE VC, Circle, Ripple, Robinhood, Republic, SpaceX, OpenAI, S&P Dow Jones Indices, Centrifuge, Anemoy, Janus Henderson, Midas, Fasanara, Morpho, Steakhouse Financial, Bitfinex Securities, Castle Community Bank, Arbra, Colb, Gemini, Arbitrum, Euroclear, Abu Dhabi Securities Exchange, FAB, HSBC, Bybit, xStocks, Dinari, BitGo, Spiko, Chainlink, MetaWealth, Securitize, Redstone, Apex Group, GLEIF, ERC-3643 Association, Kinexys by J.P.Morgan, S&P Global, Particula, 21X, GF Securities, Hashkey, OnRe, Lynq Network, European Central Bank, Ondo, Pantera, Zult, Stable, AMINA, Ripple, Paxos, World Liberty Financial, Plume, Paul Atkins/ SEC, SIFMA   Check Out Tal's Book “Investing in Revolutions”: https://www.amazon.com/Investing-Revolutions-Creating-Transformational-Technology/dp/B0DKS3YFWV#detailBullets_feature_div    TokenizeThis 2025 Conference Review: https://docsend.com/v/k8bn7/tt25  STM Predicts $30-50T in RWAs by 2030: https://docsend.com/view/7jx2nsjq6dsun2b9    More STM.co Reports: https://reports.stm.co/  Join the RWA Foundation and Read the Whitepaper: RWAF.xyz  Learn More About WALLY DAO: WallyDAO.xyz    ⏰ TABLE OF CONTENTS ⏰ 0:00 Introduction 0:16 Welcome 0:47 Market Movements 34:06 STS Interviews: Yuval Rooz, Digital Asset 45:23 RWA Foundation Updates 46:52 Token Debrief 58:18 Companies of The Week  

In this week's episode we'll learn more about a novel mouse model that recapitulates many of the properties of human sickle cell SC disease; results from the induction phase of the risk-adapted MIDAS trial of isatuximab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed, transplant-eligible multiple myeloma; and a link between splicing factor mutations and competitive fitness in myelodysplastic syndrome stem cells.Featured articles:A novel mouse model of hemoglobin SC disease reveals mechanisms underlying beneficial effects of hydroxyureaIsatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trialCell-autonomous dysregulation of interferon signaling drives clonal expansion of SRSF2-mutant MDS stem/progenitor cells

Historierna om Minotauros och labyrinten, om Herakles tolv stordåd, om Kirke och Medea har vi hört när vi var unga, och de har lämnat outplånliga avtryck i vårt medvetande. Grekisk mytologi har inspirerat människor i tre millennier – och mer därtill – och mycket av den ingår fortfarande i allmänbildningen. Disney gör filmer om den, nya romaner skrivs, och myterna står sig fortsatt starka inom barnboksfloran.Men hur uppstod dessa berättelser? Har de sina rötter i verkliga personer och händelser? Kan vi se Minotauros‑sagan som en spegling av konflikten mellan det minoiska Kreta och de helladiska städerna i södra Grekland? Var Herakles en historisk person eller en sagofigur från sten‑ eller bronsålder? Har Atlantis funnits, eller är Platons redogörelse en moraliserande skröna? Fanns kung Midas och kung Krösus – de två rikaste monarkerna i antikens Greklands kollektiva minne – över huvud taget? Och hur förklarar vi de märkliga europeiska djuren i myterna – lejon och elefanter – har de någonsin existerat i Medelhavsområdet under antiken?I sommarreprisen av podden Harrisons dramatiska historia samtalar Dick Harrison, professor i historia vid Lunds universitet, och fackboksförfattaren Katarina Harrison Lindbergh om grekiska myter och sagor.Bild: Theseus och Minotauros. A‑sida från en attisk amfora med svartfigur, ca 540 f.Kr. Wikipedia, public domain.Klippare: Aron Schuurman Producent: Urban Lindstedt Hosted on Acast. See acast.com/privacy for more information.

Warren Buffett'ın CEO bakışını mı alacaksınız, Peter Lynch'in çekim kuvvetine mi inanacaksınız, yoksa Cathie Wood'un gelecek vizyonundan da bir şeyler mi karıştıracaksınız? Kimisi ekranlara yapışarak mumlara bakıyor, kimisi kağıt kalemi önüne alıp nakit akışını çalışıyor - ama hiçbiri birbirini tam olarak anlamıyor çünkü herkesin kendine özgü bir yatırım DNA'sı var. Bu bölümde Bay Tutumlu ve İlker, temel analiz-teknik analiz savaşının ötesine geçerek kendi yatırım felsefelerini nasıl şekillendirdiklerini, hangi ustalardan ne aldıklarını ve "neden yatırım yapmamalıyım?" sorusunun Charlie Munger'dan öğrendikleri en değerli ders olduğunu anlatıyorlar. İyi dinlemeler! Midas uygulamasını indir: https://app.getmidas.com/gmih/mie6gpeu X (Twitter): https://twitter.com/getmidas Instagram: https://www.instagram.com/get_midas/ YouTube: https://www.youtube.com/@midasplus TikTok: https://www.tiktok.com/@midasinkulaklari Midas'ın Kulakları: https://www.getmidas.com/midasin-kulaklari Not: Bu içerik, içeriğin yayınlandığı günkü veriler ve haberler baz alınarak hazırlanmıştır. Eğer varsa içerikte geçen hedef fiyat tahminleri, uzman ve analist yorumları bu içeriğin yayınlandığı tarihte geçerlidir. Bu tahmin ve yorumlar zaman içinde değişkenlik gösterebilmektedir. Bu podcast'te yer alan haberler ve haberlerin içerdiği şirketler hakkındaki bilgiler yatırım danışmanlığı kapsamında değildir. Bahsi geçen hisselerdeki; hisse adı, fiyatı ve grafikleri de dahil temsilidir, yatırım tavsiyesi değildir.

Welcome to another episode of The Insurance Dudes! In this episode, Jason and Craig sit down with Cassidy Arbeli—a powerhouse agency owner whose journey is as inspiring as it is unconventional. Raised by entrepreneurial parents and equipped with a natural flair for business, Cassidy shares how she transformed her insurance career from humble beginnings with a newborn in tow to a multi-business owner, coach, and advocate for women in the industry.Cassidy opens up about the real challenges insurance agents face, from the gap in business education to the importance of building strong agency culture and the value of putting systems in place to gain real freedom. She talks candidly about what it was like to walk away from a successful captive agency to launch her own independent venture—and how that leap of faith led to even greater success and fulfillment.Join the elite ranks of P&C agents. Sign up for Agent Elite today and get exclusive resources to grow your agency!

Endeksler rekorlara koşarken, yatırımcılar iyimserlikle belirsizlik arasında ince bir çizgide yürüyor - BIST 100'ün 9.700 direncini kırması ve S&P 500'ün 7.000 hedefi gerçekçi mi, yoksa 164 milyar dolarlık sermaye girişi spekülatif balon riski mi oluşturuyor? FactSet'in analist verilerinden J.P. Morgan'ın küresel raporuna, IG Markets'in projeksiyonlarından kripto ve gümüş analizlerine kadar, 2025'in ikinci yarısında hangi sektörlerin öne çıkacağını ve hangi risklerin göz ardı edildiğini mercek altına alıyoruz. Bu bölümde fiyatlara değil temele bakarak, coşkuya değil temkinli sezgiye dayanarak nasıl pozisyon almanız gerektiğini öğreneceksiniz. İyi dinlemeler! Midas uygulamasını indir: https://app.getmidas.com/gmih/mie6gpeu X (Twitter): https://twitter.com/getmidas Instagram: https://www.instagram.com/get_midas/ YouTube: https://www.youtube.com/@midasplus TikTok: https://www.tiktok.com/@midasinkulaklari Midas'ın Kulakları: https://www.getmidas.com/midasin-kulaklari Not: Bu içerik, içeriğin yayınlandığı günkü veriler ve haberler baz alınarak hazırlanmıştır. Eğer varsa içerikte geçen hedef fiyat tahminleri, uzman ve analist yorumları bu içeriğin yayınlandığı tarihte geçerlidir. Bu tahmin ve yorumlar zaman içinde değişkenlik gösterebilmektedir. Bu podcast'te yer alan haberler ve haberlerin içerdiği şirketler hakkındaki bilgiler yatırım danışmanlığı kapsamında değildir. Bahsi geçen hisselerdeki; hisse adı, fiyatı ve grafikleri de dahil temsilidir, yatırım tavsiyesi değildir.

Why the sudden Midas touch? Blame it on global uncertainty. But gold, it's not just for pirates and pharaohs anymore! This lustrous metal has been having a moment, shining brighter than a supernova in 2024 but at about $3300 an ounce, have retail investors missed the boat? Howie Lim speaks to the experts to find out. Synopsis: Every Monday, The Business Times breaks down useful financial tips. Highlights: 01:13 Why gold has gained ground 04:26 Have you missed the boat? 08:16 Are there gold alternatives? 11:43 Gold investing strategies --- Send us your questions, thoughts, story ideas, and feedback to btpodcasts@sph.com.sg. --- Written and hosted by: Howie Lim (howielim@sph.com.sg) With Stephanie Leung, chief investment officer, StashAway; Robin Tsui, APAC gold strategist, State Street Global Advisors; and Fan Shaokai, head of Asia-Pacific (ex-China) & global head of Central Banks, World Gold Council Edited by: Howie Lim & Claressa Monteiro Produced by: Howie Lim & Chai Pei Chieh A podcast by BT Podcasts, The Business Times, SPH Media --- Follow BT Money Hacks podcasts every Monday: Channel: bt.sg/btmoneyhacks Amazon: bt.sg/mham Apple Podcasts: bt.sg/oeXe Spotify: bt.sg/oeGN YouTube Music: bt.sg/mhyt Website: bt.sg/moneyhacks Do note: This podcast is meant to provide general information only. SPH Media accepts no liability for loss arising from any reliance on the podcast or use of third party’s products and services. Please consult professional advisors for independent advice. Discover more BT podcast series: BT Correspondents: bt.sg/btcobt BT Market Focus at: bt.sg/btmktfocus BT Podcasts at: bt.sg/pcOM BT Branded Podcasts at: bt.sg/brpod BT Lens On: bt.sg/btlensonSee omnystudio.com/listener for privacy information.

Why the sudden Midas touch? Blame it on global uncertainty. But gold, it's not just for pirates and pharaohs anymore! This lustrous metal has been having a moment, shining brighter than a supernova in 2024 but at about $3300 an ounce, have retail investors missed the boat? Howie Lim speaks to the experts to find out. Synopsis: Every Monday, The Business Times breaks down useful financial tips. Highlights: 01:13 Why gold has gained ground 04:26 Have you missed the boat? 08:16 Are there gold alternatives? 11:43 Gold investing strategies --- Send us your questions, thoughts, story ideas, and feedback to btpodcasts@sph.com.sg. --- Written and hosted by: Howie Lim (howielim@sph.com.sg) With Stephanie Leung, chief investment officer, StashAway; Robin Tsui, APAC gold strategist, State Street Global Advisors; and Fan Shaokai, head of Asia-Pacific (ex-China) & global head of Central Banks, World Gold Council Edited by: Howie Lim & Claressa Monteiro Produced by: Howie Lim & Chai Pei Chieh A podcast by BT Podcasts, The Business Times, SPH Media --- Follow BT Money Hacks podcasts every Monday: Channel: bt.sg/btmoneyhacks Amazon: bt.sg/mham Apple Podcasts: bt.sg/oeXe Spotify: bt.sg/oeGN YouTube Music: bt.sg/mhyt Website: bt.sg/moneyhacks Do note: This podcast is meant to provide general information only. SPH Media accepts no liability for loss arising from any reliance on the podcast or use of third party’s products and services. Please consult professional advisors for independent advice. Discover more BT podcast series: BT Correspondents: bt.sg/btcobt BT Market Focus at: bt.sg/btmktfocus BT Podcasts at: bt.sg/pcOM BT Branded Podcasts at: bt.sg/brpod BT Lens On: bt.sg/btlensonSee omnystudio.com/listener for privacy information.

Episode 21In this podcast, professional astrologers Chani Nicholas, Thea Anderson, and Eliza Robertson look to the sky to make sense of what's happening here on Earth.This episode brings you into the astrological group chat to talk through how Jupiter's long-awaited entrance into Cancer (and its recent square to Saturn) have landed IRL. Covering everything from Tina Knowles' memoir “Matriarch” and the first-ever CHANI Pop-Up to the No Kings protests, the Israel–Iran conflict, and the NYC mayoral race, we look at how the most anticipated astrology of 2025 has manifested in the collective so far. We also reflect on some of 2025's other milestone astro (hey, Pluto in Aquarius and Neptune in Aries), dig into how those transits have played out historically, and prep for what's ahead with Uranus in Gemini. These are unprecedented — yet eerily familiar — times, and we've got the charts and chats to help make sense of it all. So let's dive in.Content warning: mentions of sexual predation, genocide, murder, police brutality, and forced pregnancyTimestamps:(00:00) - Welcome to Down to Astro episode 21(00:41) - Jupiter in Cancer: An era of hope and connection(01:50) - The CHANI Pop-Up: community engagement and collective care(13:26) - The impact of the Saturn square on Jupiter's abundance(15:32) - Iran's chart and the Israel–Iran conflict(27:13) - Comparing ancient astrological predictions and current events(30:14) - The growing power of local movements with Jupiter in Cancer(32:53) - ICE protests, No Kings, and the misuse of military force(38:48) - Uranus in Gemini: Historical astrological parallels and predictions(44:27) - Neptune in Aries, NATO's chart, and redrawing international alliances(54:40) - Mars square Uranus: Israel's initial strikes on Iran(59:15) - Uranus in Gemini and the US on the brink of war(01:04:30) - The shifting world order and the need for human connection(01:07:40) - The future of intelligence, tech, and critical thinking(01:12:19) - Tina Knowles' memoir “Matriarch” and the power of art and generosity(01:18:45) - Beyoncé's Requiem for America(01:25:11) - Ask us anything: What does it mean if I'm in my Neptune square?This episode was recorded on 06/24/2025.For more astrological insights, download the CHANI app or follow CHANI on Instagram, TikTok, and Bluesky.The song “Midas,” featured in the podcast, was created by NISHA and is available wherever you listen to music.This episode also mentioned the following creative works:Ali A. Olomi's translations from Abu Mashar“Matriarch: A Memoir" by Tina KnowlesThe works of Kelly Surtees The works of Nick Dagan BestP.S. The transcript for this episode is available here.

Finance is undergoing a radical transformation that's redefining how we think about money, technology, and trust. The latest edition of Finance X Magazine pulls back the curtain on these changes, revealing a landscape where artificial intelligence has moved from experimental to essential.The numbers tell a compelling story: 85% of Belgian financial institutions now maintain dedicated AI units—a staggering jump from just 37% last year. This isn't superficial adoption; it's a fundamental strategic pivot affecting everything from talent development to organizational structure. Graph LLMs are emerging as particularly powerful tools, connecting complex data points to detect fraud patterns and personalize customer experiences with unprecedented precision.Beyond AI, we explore how geography and regulation are reshaping global fintech. Europe has become a magnetic destination for Asian fintech expansion thanks to its passporting system—one license unlocks an entire continent. Meanwhile, in Turkey, a startup called Midas achieved the seemingly impossible: doubling the country's investor base in just three years by slashing trade fees from $25 to $1.50 and eliminating minimum balances. Their story demonstrates how technological innovation can create "financial armor" against economic instability.For established players, adaptation is essential but complex. AXA Partners shows how embedding insurance directly into partner journeys creates seamless customer experiences. Yet Solaris serves as a cautionary tale of growth outpacing operational controls, resulting in regulatory fines and reputational damage. The striking parallel drawn between legacy banks and Yellowstone's John Dutton perfectly captures their challenge: leveraging valuable existing assets while avoiding obsolescence.As technology accelerates and regulations tighten—from NIS2 cybersecurity requirements to comprehensive crypto frameworks—financial institutions face a profound question: How do we balance innovation with stability, and ultimately, how do we maintain trust at the center of everything we do? Join us as we navigate these crucial questions reshaping the future of finance.Thank you for tuning into our podcast about global trends in the FinTech industry.Check out our podcast channel.Learn more about The Connector. Follow us on LinkedIn.CheersKoen Vanderhoydonkkoen.vanderhoydonk@jointheconnector.com#FinTech #RegTech #Scaleup #WealthTech

Welcome to another episode of The Insurance Dudes! In this powerful conversation, hosts Jason Feltman and Craig Pretzinger sit down with Dan Kitajima to unpack a truly wild journey from building a $17 million captive insurance agency to making the bold leap into the independent world.Dan shares the highs and lows of his experience—from signing a jaw-dropping $20,000/month office lease just before his carrier pulled the rug out by non-renewing $6 million in policies, to learning how to pivot, retain clients, and ultimately rebuild—this time with even greater focus, flexibility, and profitability. The trio dives into the nuances of switching from captive to independent, breaking down differences in closing ratios, broker fees, marketing strategies, and what it really takes to survive (and thrive) through massive industry disruption.Join the elite ranks of P&C agents. Sign up for Agent Elite today and get exclusive resources to grow your agency!

Portföy ekranındaki kırmızı rakamları gördüğünüzde hissettiğiniz o ağır boşluk, aslında 13.3 milyon kişilik bilimsel araştırmanın da doğruladığı evrensel bir deneyim. Borsa getirilerindeki düşüşler sadece cüzdanları değil, antidepresan satışlarını %0,42 oranında artırarak zihinleri de derinden etkiliyor - çünkü Daniel Kahneman'ın loss aversion teorisine göre beynimiz kayıpları kazançlardan iki kat daha yoğun hissediyor. Bu bölümde amigdala'nın savaş-kaç-don tepkisinden disposition effect'e, 2025'in volatil günlerinde ruh sağlığınızı koruyarak nasıl sadece kazanan değil, aynı zamanda iyi hisseden bir yatırımcı olabileceğinizi bilimsel verilerle açıklıyoruz.İyi dinlemeler!Midas uygulamasını indir: https://app.getmidas.com/gmih/mie6gpeuX (Twitter): https://twitter.com/getmidasInstagram: https://www.instagram.com/get_midas/YouTube: https://www.youtube.com/@midasplusTikTok: https://www.tiktok.com/@midasinkulaklariMidas'ın Kulakları: https://www.getmidas.com/midasin-kulaklariNot: Bu içerik, içeriğin yayınlandığı günkü veriler ve haberler baz alınarak hazırlanmıştır. Eğer varsa içerikte geçen hedef fiyat tahminleri, uzman ve analist yorumları bu içeriğin yayınlandığı tarihte geçerlidir. Bu tahmin ve yorumlar zaman içinde değişkenlik gösterebilmektedir. Bu podcast'te yer alan haberler ve haberlerin içerdiği şirketler hakkındaki bilgiler yatırım danışmanlığı kapsamında değildir. Bahsi geçen hisselerdeki; hisse adı, fiyatı ve grafikleri de dahil temsilidir, yatırım tavsiyesi değildir.

In this episode of Got Clutter? Get Organized, I'm joined by Stephanie Warlick—Founder and CEO of 5FT View Consulting—for a powerful conversation on organizing your business strategy before the year ends. Stephanie shares her journey from struggling student to business strategist with the Midas touch and reveals the five biggest “gotchas” that often derail small business owners. If you're feeling buried in decisions, details, and daily demands, this episode will help you clear the mental and operational clutter and refocus on what truly matters in Q3.

El Dr. Adrián Alejandro Ceballos López, hematólogo adscrito a la Clínica de Mérida en Yucatán, comparte su análisis de los estudios más relevantes sobre hematología presentado durante la Reunión Anual 2025 de la Sociedad Americana de Oncología Clínica, celebrada en Chicago, con base en la información disponible al momento de esta grabación.Los trabajos comentados son:CARTITUDE-1 (abstract #7507)SEQUOIA  brazo C (abstract #7011)SEQUOIA brazo D (abstract #7009)MIDAS (abstract #7500)VERIFY  (abstract #LBA3)Material exclusivo para profesionales de la salud. Este material ha sido desarrollado únicamente con fines educativos e informativos y no tiene la intención de sustituir el juicio clínico de los profesionales de la salud.Las opiniones y declaraciones presentadas en este contenido son responsabilidad exclusiva de los ponentes y no reflejan necesariamente la postura institucional de ScienceLink ni de terceros mencionados. La información presentada se basa en el conocimiento y la experiencia profesional de los ponentes. La veracidad, exactitud y actualidad científica de los datos son de su exclusiva responsabilidad. Así mismo garantizan que el contenido utilizado no infringe derechos de autor de terceros y asumen toda responsabilidad por su uso.Se deberán de revisar las indicaciones aprobadas en el país con estricto apego al marco regulatorio aplicable para cada uno de los tratamientos y medicamentos comentados. ASCO® es una marca registrada de la American Society of Clinical Oncology. Este material ha sido producido de manera independiente y no está autorizado, patrocinado ni avalado por dicha organización.

Um den König Midas von Phrygien dreht sich die heutige Folge. Midas Begegnung mit Silenius über das Übermaß dem dionysischen Rausch und Dionysos, und dem einen Wunsch, den Dionysos ihm gewährte. Midas wählte sich, dass alles was er anfasst zu glänzend goldenem Gold wird. Was der Wunsch des superreich werden Wollens mit unserer heutigen Zeit der Maßlosigkeit und dem Wunsch der lebenden Superreichen noch mehr Reichtum zu erhalten gemein hat, besprechen Christoph Quarch und die Geschichtenerzählerin Barbara Goossens #griechischemythen #Gier #Übermaß #dionysos #mythologieverstehen #mythen #akademie3 #christophquarch

Dr. John Sweetenham and Dr. Marc Braunstein highlight top research on hematologic malignancies from the 2025 ASCO Annual Meeting, including abstracts on newly diagnosed chronic phase CML, relapsed B-cell lymphoma, and multiple myeloma. Transcript Dr. John Sweetenham: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham. On today's episode, we'll be discussing promising advances in newly diagnosed chronic phase CML, relapsed B-cell lymphoma, multiple myeloma, and other hematologic malignancies that were presented at the 2025 ASCO Annual Meeting. Joining me for this discussion is Dr. Marc Braunstein, a hematologist and oncologist at the NYU Perlmutter Cancer Center. Our full disclosures are available in the transcript of this episode.  Marc, there were some great studies in the heme space at this year's Annual Meeting, and it's great to have you back on the podcast to highlight some of these advances. Dr. Marc Braunstein: Yes, I agree, John, and thank you so much for inviting me again. It's great to be here.  Dr. John Sweetenham: Let's start out with Abstract 6501. This was a study that reported on the primary endpoint results of the phase 3B ASC4START trial, which assessed asciminib versus nilotinib in newly diagnosed chronic phase CML. And the primary endpoint of this, as you know, was time to treatment discontinuation because of adverse events. Can you give us your insights into this study? Dr. Marc Braunstein: Absolutely. So, like you mentioned, you know, asciminib is an allosteric inhibitor of the BCR-ABL kinase that has activity in CML, and that includes patients with the T315I mutation that confers resistance to first- and second-generation TKIs. So, the ASC4FIRST study, which was published last year in the New England Journal of Medicine, showed superior efficacy of asciminib compared to investigator-selected first- or second-generation TKIs, actually leading to the FDA approval of asciminib in first-line CML. So, the authors of that study presented data at this year's ASCO meeting from the phase 3 ASC4START comparing safety and time to discontinuation due to adverse events of asciminib versus nilotinib, a second-generation TKI. So, 568 patients with newly diagnosed CML were randomized one-to-one to once-daily asciminib or twice-daily nilotinib. So, at a median follow-up of 9.7 months, about 11% in the asciminib group and 17% in the nilotinib group discontinued treatment, with significantly fewer discontinuations with asciminib due to adverse events. There was also a secondary endpoint of major molecular response, which was also better with asciminib. For example, the MR 4.5, which is a deep response, was 2.5% versus 0.4% favoring asciminib by week 12. So, I think in conclusion, these results build on the ASC4FIRST study, making the case for the superior safety and efficacy of asciminib versus other first- or second-generation TKIs in newly diagnosed CML. Dr. John Sweetenham: Thanks, Marc. Do you think this is going to change practice? Dr. Marc Braunstein: I think so. I think there are still some questions to be answered, such as what resistance mutations occur after first-line treatment with asciminib. But I think the sum of these studies really make the case for using asciminib upfront in CML. Dr. John Sweetenham: Okay, great. Thank you. And let's move on to our second abstract. This was Abstract 7015 and was reported from Mass General Hospital. And this was a study in patients with relapsed and refractory diffuse large B-cell lymphoma and reported the 2-year results of the so-called STARGLO study. This is a comparison of glofitamab, a T-cell engaging bispecific antibody, with gemcitabine and oxaliplatin in this group of patients. Can you tell us a little bit about your impressions of this study? Dr. Marc Braunstein: Absolutely. So just for background, the treatment landscape for relapsed/refractory large B-cell lymphoma is expanding, now with two bispecific antibodies targeting CD20 that are approved after two or more lines of therapy. Among these, glofitamab was approved in 2023 based on phase 2 data showing an objective response rate of 52%, with 39% complete responses in relapsed/refractory large B-cell lymphoma patients after a median of three prior lines of therapy. Distinguishing glofitamab from epcoritamab, the other approved bispecific, glofitamab was given for 12 cycles and then stopped. Additionally, when combined with gemcitabine and oxaliplatin in the phase 3 STARGLO study, there was significantly improved overall survival compared to rituximab plus gemcitabine and oxaliplatin in transplant-ineligible relapsed/refractory large B-cell lymphoma patients at a median follow-up of 11 months.  The authors of that study published last year in Lancet now present at ASCO this year the 2-year follow-up of the STARGLO study. Two hundred and seventy-four patients with a median of one prior line of therapy were randomized two-to-one to glofitamab plus GemOx versus rituximab plus GemOx, with the primary endpoint of overall survival. Here, the median overall survival was not reached versus 13.5 months, with a median PFS also significantly improved at about 14 months versus 4 months in the control. CRS of note in the glofitamab arm was mostly grade 1 or 2, with only about 2.3% grade 3 events. And three of the four patients had grade 1 or 2 neurotoxicity. So, John, putting this into context, I think it's encouraging that we now have randomized data showing the superiority of a bispecific plus chemotherapy over rituximab plus chemotherapy in transplant-ineligible patients. And while only 8% of the patients in the STARGLO study had prior anti-CD19 CAR T-cell therapy, I think this regimen could be considered in those patients who are ineligible for transplant or CAR T-cell therapy. Dr. John Sweetenham: Yeah, I agree. I think a couple of other compelling numbers to me were the fact that around 55% of these patients were alive at 2 years in the group who'd received glofitamab, and that almost 90% of those having that arm of the study who had a CR at the end of treatment were alive at 12 months. So, clearly, it's an active agent and also a kind of great off-the-shelf fixed-duration alternative in these relapsed and refractory patients. Dr. Marc Braunstein: I agree, and I would also note that the phase 3 SKYGLO study is looking at glofitamab plus Pola-R-CHP versus Pola-R-CHP alone. So, we may even be using these eventually in the first-line setting. Dr. John Sweetenham: Absolutely. Let's stay on the theme of diffuse large B-cell lymphoma and look at one other abstract in that space, which was Abstract 7000. This was a study from the HOVON group in the Netherlands, which looked at the prospective validation of end-of-treatment circulating tumor DNA in the context of a national randomized trial. What are your thoughts on this? Dr. Marc Braunstein: So, non-invasive liquid biopsies to detect and monitor cancers via circulating tumor-derived DNA or ctDNA, you know, is really emerging as a valuable tool in both solid and liquid tumors to understand disease biology, and also for drug development. So, to date, the most established application of ctDNA in lymphoma, I would say, is really for monitoring of minimal residual disease. So, in this correlative study by Steven Wang and colleagues in the HOVON group, they evaluated the prognostic significance of MRD status as assessed by ctDNA following first-line treatment with curative intent with either R-CHOP or dose-adjusted R-EPOCH. At the end of treatment, encouragingly, 76% of patients were MRD-negative, and 24% were MRD-positive. Now, of note, MRD-positive status at the end of treatment predicted inferior progression-free survival at 2 years, with only 28% of patients who are MRD-positive being progression-free versus 88% who are MRD-negative. And in fact, all the patients who failed to achieve a complete response after first-line treatment and were MRD-positive ultimately relapsed. So, circulating tumor cells are rarely found in large B-cell lymphomas, and so this study really builds on accumulating data that ctDNA has clinical value to detect residual disease with a non-invasive approach. So, there are many implications of how we could potentially use this to detect early signs of relapse, to potentially escalate treatment for consolidation if patients remain MRD-positive. So, I think this will eventually become utilized in clinical practice. Dr. John Sweetenham: Yeah, I agree. I think it's interesting that it provided an independent assessment of response, which was independent, in fact, of the results of PET-CT scanning and so on, which I think was very interesting to me. And the authors of the abstract actually commented in their presentation that they think this should be integrated as part of the standard response assessment now for patients with large B-cell lymphoma. Would you agree with that? Dr. Marc Braunstein: I would. For one thing, it allows repeated sampling. It's a non-invasive approach; it doesn't necessarily require a bone marrow biopsy, and it may have more sensitivity than conventional response measures. So, I think having a standardized system to assess ctDNA will be helpful, and definitely, I think this will be a valuable biomarker of disease response. Dr. John Sweetenham: Okay, great. Thanks. We're going to change gear again now, and we're going to highlight two abstracts in the multiple myeloma space. The first one of these is Abstract 7507. And this abstract reported on the long-term results of the CARTITUDE study for patients with relapsed and refractory multiple myeloma. What are your comments on this presentation? Dr. Marc Braunstein: So, this study actually got a lot of press, and I've already had multiple patients asking me about CAR T-cells as a result. Just as some background, CAR T-cells targeting BCMA, which is pretty much universally expressed on malignant plasma cells in myeloma, have really shown remarkable responses, especially in heavily pretreated patients, showing superior progression-free survival in both later and earlier phases of the disease, including in randomized studies in patients with second-line or beyond. So, the CARTITUDE-1 was really the original Phase 1/2 study of ciltacabtagene autoleucel, one of the two approved anti-BCMA CAR T-cell products, which was investigated in patients with a median of six to seven prior lines of therapy. So, these were patients who were pretty heavily pretreated. So, in the study presented by Voorhees at this year's ASCO meeting, this was the long-term follow-up at a median of 5 years from the one-time CAR infusion in these patients with a median of five prior lines of therapy. And remarkably, of the 97 patients, 33% remained progression-free at 5 years plus, without needing any further myeloma treatment during that time. And among those 33% of patients, 23% had high-risk cytogenetics, which we know are notoriously difficult to achieve responses in. What was interesting that they presented as correlative studies was there were some biomarkers that were distinguishing the patients who had the long PFS, including enrichment of more naive T-cells in the product, lower neutrophil-to-T-cell ratio, higher hemoglobin and platelets at baseline, and higher CAR T-cell levels relative to soluble BCMA levels. And the fact that they reported a median overall survival of 61 months in these really heavily pretreated patients, I think these data are impressive. I think we're going to continue to be using CAR T even earlier in the disease status than fifth or sixth line, as it was studied in CARTITUDE-1. There are even ongoing studies looking at first-line treatment with CAR T-cells. Dr. John Sweetenham: So, do you think that those 33% of patients who are disease-free at 5 years, do you think any of those are cured?  Dr. Marc Braunstein: That was one of the headlines in the press. I think if we're going to discuss things like "operational cures," where we're transforming myeloma into really a chronic disease, where patients can live practically a normal life expectancy, I think the measure of 5 years, especially in this population that was explored in CARTITUDE-1, I think we can call that close to a cure. Dr. John Sweetenham: Okay. Well, thank you. Exciting data, for sure. We're going to conclude today with another abstract in the multiple myeloma space. And this was Abstract 7500, which looked at an MRD, minimal residual disease-driven strategy following induction and transplant-eligible newly diagnosed multiple myeloma patients and reported on the primary endpoints of the phase 3 MIDAS trial. Can you walk us through this one, Marc? Dr. Marc Braunstein: Absolutely. It is a bit more complicated than the prior one we discussed because this is a randomized study with four arms. So, I'll start by saying that anti-CD38-based quadruplet regimens continue to show superior outcomes in both transplant-eligible and -ineligible newly diagnosed multiple myeloma patients. The MIDAS study mentioned is an open-label phase 3 trial with four arms in transplant-eligible newly diagnosed myeloma patients.  And initially, these patients were all treated with quadruplet therapy with the anti-CD38 antibody isatuximab combined with carfilzomib, lenalidomide, and dexamethasone in 718 newly diagnosed myeloma patients. So, they received the quadruplet regimen for six cycles and then were randomized based on their MRD status at 10 to the negative fifth following six cycles of induction. And that first randomization, if they were MRD-negative, was to either consolidation with six more cycles of the quadruplet regimen or transplant, autologous transplant, plus two cycles additionally of the quadruplet regimen. And both arms were followed by lenalidomide maintenance. The primary endpoint was MRD negativity at 10 to the negative sixth prior to entering the lenalidomide maintenance component. And in addition, the patients who were MRD-positive after induction were randomized to transplant plus two cycles of consolidation or a tandem autologous transplant. So, the median follow-up of the study was about 16 months, and the pre-maintenance rate of MRD negativity was high, between 84 to 86% between the two arms who were MRD-negative, which was not significantly different. And as far as the 233 patients who were MRD-positive, the pre-maintenance MRD negativity was also not significantly different at 40% for those who received autologous transplant, and 32% who received a tandem transplant. So, there's a lot of debate in the myeloma field about the evolving role of autologous transplant and whether transplant still plays a significant role in patients who are either MRD-negative after induction or who have deep remissions and are of standard risk. So, I think these data suggest that patients who are MRD-negative after induction with a quadruplet regimen studied here, which was Isa-KRd, plus consolidation, may possibly be able to forego consolidation with autologous transplant. And likewise, for those patients who are MRD-positive after induction, tandem transplant didn't seem to provide much of a benefit compared to single transplant, which is consistent with prior studies such as the StaMINA study. Dr. John Sweetenham: So, where do you think this leaves us, Marc? Are we going to need more studies before we have any definitive guidance on whether an autologous transplant is still appropriate for those patients who are MRD-negative? Dr. Marc Braunstein: Well, as clinicians, we want to do what's best for our patient. And in myeloma, the best we can do is to get as deep remissions as possible, meaning MRD negativity. And so, I think it's clear from the MIDAS study and others that quadruplet regimens provide the deepest remissions when given upfront. We can debate the role of autologous transplant. I think certainly the role of tandem autologous transplant is fading. But as far as a single autologous transplant as consolidation, I think it's reasonable as a goal to try to achieve MRD negativity after the transplant, especially for patients who remain MRD-positive after induction. Dr. John Sweetenham: Okay, great. Marc, thanks as always for sharing your insights on the heme malignancies studies from the ASCO meeting this year and for joining us on the ASCO Daily News Podcast. Always appreciate hearing your thoughtful and balanced input on these. Dr. Marc Braunstein: My pleasure. Thank you, John. Dr. John Sweetenham: And thank you to our listeners for joining us today. You'll find links to the abstracts discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Find out more about today's guest:  Dr. John Sweetenham Dr. Marc Braunstein   @docbraunstein     Follow ASCO on social media:   @ASCO on Twitter  ASCO on Bluesky  ASCO on Facebook   ASCO on LinkedIn     Disclosures:  Dr. John Sweetenham:  Consulting or Advisory Role: EMA Wellness  Dr. Marc Braunstein:  Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb/Celgene, Adaptive Biotechnologies, GlaxoSmithKline, ADC Therapeutics, Janssen Oncology, Abbvie, Guidepoint Global, Epizyme, Sanofi, CTI BioPharma Corp  Speakers' Bureau: Janssen Oncology  Research Funding (Institution): Janssen, Celgene/BMS

The Bulletproof Dental Podcast Episode 399 HOSTS: Dr. Peter Boulden and Dr. Craig Spodak GUEST: Amir Mansouri, SprintRay DESCRIPTION In this episode of the Bulletproof Dental Practice Podcast, Dr. Amir Mansouri, co-founder of SprintRay, shares his journey into 3D dental printing and discusses how this technology is transforming dental practices. The conversation covers the evolution of dental technology, the importance of patient experience, and why practices must adopt 3D printing to stay competitive. Dr. Mansouri also explores the integration of AI in dental design, the role of empowering dental staff, and how these innovations are improving patient care through same-day solutions. TAKEAWAYS SprintRay simplifies 3D printing for dental practices, with Dr. Mansouri's engineering background driving innovation Over 60% of dental practices now use digital solutions like intraoral scanners Night guards are the ideal starting point for practices new to 3D printing Material science challenges are being addressed through Sprint Ray's high ceramic content MIDAS technology The future will see coexistence of milling and printing, with same-day dentistry favoring 3D solutions Entry-level 3D printers now cost around $10,000, while ovens range $10,000-$15,000 AI is simplifying dental design processes and empowering dental assistants Same-day restorations improve patient care and reduce temporary retention issues User-friendly technology is essential for successful staff implementation The dental industry thrives on collaboration and continuous innovation CHAPTERS 00:00 Introduction to Dr. Amir Mansouri and SprintRay 02:01 The Journey into 3D Dental Printing 10:08 Progression of 3D Printing Applications 11:48 The Importance of Patient Experience 13:05 Current State of 3D-Printed Restorations 16:05 Advancements in Material Science 20:52 The Future of 3D Printing in Dentistry 29:10 Understanding the Cost of Dental Technology 35:05 3D Printing in Dentistry: Accessibility and Cost 37:04 The Role of AI in Dental Design 39:55 Empowering Dental Assistants with Technology 44:01 The Future of Dentistry: Innovation and Collaboration   REFERENCES Bulletproof Summit Bulletproof Mastermind

On this episode of The Insurance Dudes, hosts Craig Pretzinger and Jason Feltman sit down with BJ Hill, owner of Summit Insurance in Loveland, Colorado. BJ shares his remarkable journey from college basketball coach to building one of the top insurance agencies in the country, now writing over $18 million in premium. From his early days as a “juco” coach and experiencing a steep learning curve buying his first $3 million agency, to overcoming challenges like passing industry exams and developing his leadership style, BJ gets candid about the grind, the setbacks, and the drive required to scale a business.Tune in as BJ reveals the secrets to coaching and developing a winning insurance team, the importance of culture and accountability, and the lessons he's learned from both sports and entrepreneurship. His unique perspective shows how building champions—on the court or in the agency—always comes down to grit, self-awareness, and relentless improvement. Plus, you'll hear some wild agency stories, tactics for onboarding and motivating staff, and BJ's best advice for fellow agency owners who want to scale up. Get ready for an inspiring, actionable conversation, packed with real-world insights for insurance pros and business leaders alike!Join the elite ranks of P&C agents. Sign up for Agent Elite today and get exclusive resources to grow your agency!

Quique seeks answers. Midas seeks retribution. Content Notes: Fire SFX, Explosion SFX, Phone Ring SFX, Hallie yelling a lot Character List: docs.google.com/document/d/1QLtdBJBznVKM9dUkPs_Z1JemAulyK96WIm5xBr7W0jU/edit?usp=sharing Follow Quest Friends! online Website: ⁠⁠⁠questfriendspodcast.com⁠⁠⁠  Patreon: ⁠⁠⁠patreon.com/questfriends⁠⁠⁠ Everything else: ⁠⁠⁠linktr.ee/questfriendspodcast⁠⁠ Music Credits "Quest Friends! Hereafter Theme" by Miles Morkri: ⁠⁠⁠twitter.com/milesmorkri⁠⁠⁠ "Spooky Halloween Night Cut D" by AdiGoldstein: ⁠⁠⁠pond5.com/royalty-free-music/item/75369121-spooky-halloween-night-cut-d⁠⁠ Additional Music from Motion Array: ⁠⁠⁠motionarray.com/ Learn more about your ad choices. Visit megaphone.fm/adchoices

Galvia AI, a leading international artificial intelligence company, has announced its UK expansion with a new Manchester office and plans for job creation in the region. Headquartered in Galway, Ireland, Galvia will base its UK operations at the Turing Innovation Catalyst (TIC), within Sister - Manchester's £1.7bn science and technology innovation district. Galvia unifies business data and turns it into connected intelligence that predicts, prompts, and drives smarter decisions in real time. The Manchester investment is set to create double-digit job growth and reinforce the city's position as a growing hub for AI and digital innovation. Galvia's clients range from SMEs in retail, hospitality, and manufacturing to global organisations such as Atos, Nestlé, NTT Data Business Solutions, and several top-ranking universities. At a high-profile launch event held on 3rd June 2025 at TIC, Galvia unveiled plans to empower SMEs across Greater Manchester and the North West to harness the power of AI. The event gathered business leaders, policymakers, and AI innovators, highlighting the strategic importance of Galvia's UK expansion. Commenting on Galvia's UK launch at the Turing Innovation Catalyst, Councillor Bev Craig, Leader of Manchester City Council, said: "Manchester has always been a place where ideas thrive and businesses scale with purpose. We're excited to welcome Galvia to Manchester and support the launch of their accelerator programme - a real opportunity for local SMEs to engage with the potential of AI in a practical, meaningful way. By removing barriers to AI adoption, initiatives like this can help unlock the region's entrepreneurial potential and ensure innovation is accessible to all." John Clancy, CEO and Founder of Galvia AI, said: "We're excited to establish roots in Manchester - a city with a dynamic tech ecosystem and a clear vision for innovation. Our goal is to empower SMEs by removing barriers to AI adoption and providing practical, scalable solutions that integrate seamlessly with existing systems." SMEs often struggle to make use of their data due to siloed systems and limited resources. Galvia addresses this gap with trusted technology that has been developed for both enterprises and SMEs since its founding in 2017. It brings together data from across an organisation, unlocking new insights, driving improvement and enhancing profitability. At the heart of Galvia's Manchester strategy is the Galvia AI Adoption Accelerator, a 5-week programme launching in September in partnership with TIC and law firm Addleshaw Goddard. It's designed to give SME leaders a clear understanding of what to do with their data and a strategic plan of how to integrate AI into their business. The Accelerator is central to Galvia's mission to make AI work for all - providing SMEs with a fast, practical route to leveraging their data and driving growth through innovation. Galvia also intends to partner with SME technology providers in sectors such as retail and hospitality to apply the benefits of AI to their platforms. "AI isn't just for big-budget tech businesses. It can and should make a real, tangible difference for SMEs, which are the core of the economy," added John Clancy. "Together with our partners, we're very proud to bring our accelerator programme to Manchester. It's already proven highly successful in Ireland, equipping participants with the knowledge and tools to stay ahead of industry changes and maintain a competitive edge. "We bring seven years of real-world experience in AI - and in AI years, that's a lifetime. We've worked with organisations and data sets of all sizes to make AI deliver real strategic value." Joe Manning, Managing Director at MIDAS, Manchester's Inward Investment Agency said: "Ireland is one of Greater Manchester's most important markets, with a whole host of Irish companies choosing to expand here. "We're very pleased to welcome Galvia, with their decision to set up a UK base in our city-region re...

Pianistas, parem de tentar. A melhor gravação dos "Noturnos de Chopin" é de Maria João Pires. A pianista traz-nos o seu toque de Midas que comprova, mais uma vez, a sua sensibilidade musical. See omnystudio.com/listener for privacy information.

In this episode of The Insurance Dudes, hosts Craig and Jason sit down with Patrick Albrecht, President of Associated Insurance Administrators (AIA), to discuss the evolution of commercial insurance marketing and sales. Patrick shares his journey from Air Force engineer to insurance executive, offering valuable insights into the wholesale insurance business.Learn about effective niches in commercial insurance, including healthcare, municipalities, and forestry products. Patrick discusses how the insurance industry has transformed from door-to-door sales to modern data-driven approaches, while emphasizing that relationships remain key to success.Join the elite ranks of P&C agents. Sign up for Agent Elite today and get exclusive resources to grow your agency!

Welcome back to another exciting episode of The Insurance Dudes! Today's guest is none other than Dave Williams, a dynamic entrepreneur with a fascinating journey from overcoming personal and professional challenges to building a multi-million dollar insurance agency. Dave shares his insights on the importance of mastering your craft from the ground up, the power of cultivating a positive company culture, and the transformative effects of focusing on health and well-being. We dive deep into his process of scaling an insurance business through effective sales funnels, innovative hiring practices, and maintaining a strong growth mindset.Whether you're an agency owner or aspiring entrepreneur, this episode is packed with valuable lessons and inspiration to fuel your path to success. So, get ready as we hit the ground running with Recruit King Dave Williams, only on The Insurance Dudes!Join the elite ranks of P&C agents. Sign up for Agent Elite today and get exclusive resources to grow your agency!

Welcome back to The Insurance Dudes! In this episode, hosts Jason Feldman and Craig Pretzinger sit down with industry powerhouse Peter Fournier to uncover the secrets behind building a thriving, recession-proof insurance agency. Peter shares his journey from flipping Pokémon cards as a kid to carving out his niche in mortgage protection within the insurance world. He dishes out hard-earned lessons on money management, the critical importance of process, and how mastering referrals transformed his business. You'll get candid stories from the field, tips on holding yourself accountable, and actionable advice for new and seasoned agents alike.Whether you're looking to break free from the grind of cold leads or level up your agency sales game, there's a ton of wisdom packed into this lively and insightful conversation. So grab your notepad, and let's dive in!Join the elite ranks of P&C agents. Sign up for Agent Elite today and get exclusive resources to grow your agency!

Welcome to this episode of The Insurance Dudes, where hosts Jason and Craig sit down for a high-energy, no-holds-barred conversation with the dynamic David Carothers.David shares his unconventional journey from a college baseball player and retail worker living off macaroni and cheese to running a powerhouse commercial insurance agency in Tampa. In this episode, you'll hear how David's unique hiring process—bringing in producers from outside the insurance industry—and his out-of-the-box, yet structured approach have set his agency apart. He talks candidly about building a resilient culture, the importance of self-belief, and getting creative within the strict confines of insurance regulations. With plenty of laughs, practical advice, and raw insights, David lays out exactly what it takes to thrive in this business, even when the odds—and your bank account—are stacked against you.Whether you're new to insurance or a seasoned pro, this episode is packed with the energy and wisdom you need to go out and get it.Join the elite ranks of P&C agents. Sign up for Agent Elite today and get exclusive resources to grow your agency!

Welcome to another exciting episode of "The Insurance Dudes," where hosts Craig Pretzinger and Jason Feltman are on a mission to help you escape the constraints of your insurance agency with the secrets to creating a predictable and profitable sales machine. In this episode titled "Audio Make Leads Paid For Put Your Thimble On Front Of Funnel," we have a fascinating guest, Jay Bregman, who takes us on his entrepreneurial journey in the insurance industry.Jay shares how his passion for drone piloting unexpectedly led him to identify a gap in the market—drone pilots struggling to secure insurance for their gigs. This revelation sparked the creation of Thimble, a company dedicated to simplifying the world of small business insurance. Jay delves into the nuances of building his team and the challenges of sticking to a disciplined business model as they expanded from insuring drone pilots to servicing a myriad of small business professionals with a modern approach.Join the elite ranks of P&C agents. Sign up for Agent Elite today and get exclusive resources to grow your agency!

Welcome to another exciting episode of "The Insurance Dudes," where hosts Craig Pretzinger and Jason Feltman are on a mission to help you escape the constraints of your insurance agency with the secrets to creating a predictable and profitable sales machine. In this episode titled "Audio Make Leads Paid For Put Your Thimble On Front Of Funnel," we have a fascinating guest, Jay Bregman, who takes us on his entrepreneurial journey in the insurance industry.Throughout the episode, Jay offers invaluable insights for insurance agents and entrepreneurs alike, emphasizing the importance of adaptability and endurance in an ever-evolving industry. He highlights the advantages of embracing new technologies early on to stay ahead of the curve and maximize opportunities. Don't miss this engaging conversation packed with practical advice on how you can leverage insurtech innovations to transform your own agency. Grab your notepads, and let's dive into the world of insurance with the always inspiring Jay Bregman!Join the elite ranks of P&C agents. Sign up for Agent Elite today and get exclusive resources to grow your agency!

On this episode of The Insurance Dudes, Jason and Craig sit down with David Kelly, the author who literally wrote the book on incentive compensation management and the founder of insuretech startup BobTrack. David shares his unconventional journey into the insurance industry—starting as a complete outsider who's never sold a policy but knows how to turn tangled insurance data into actionable insights. We delve into the legacy technology challenges facing carriers and agencies, from mainframes that are older than most agents to the complexities of integrating new software.David reveals how his solutions help agencies not only forecast and reconcile commissions, but also gain a clearer picture of their book of business by integrating with existing agency management systems. The conversation also peels back the curtain on why incentive comp is such a headache for insurers, and how better data tracking can uncover missing commissions and streamline agency finances.Join the elite ranks of P&C agents. Sign up for Agent Elite today and get exclusive resources to grow your agency!

Welcome to another exciting episode of The Insurance Dudes Podcast! Today, we have a special guest, Brian Ahearn. With his extensive experience in the insurance industry and expertise in the psychology of persuasion, Brian shares invaluable insights that can help transform your agency operations and enhance your sales skills. From the importance of building genuine relationships to leveraging principles of psychology in everyday interactions, Brian offers a wealth of knowledge that is sure to elevate your professional game.Whether you're a seasoned agent or new to the industry, you won't want to miss this enlightening conversation packed with tips and strategies to create a more predictable and profitable agency. Tune in for this engaging discussion that dives deep into understanding human behavior, client interactions, and the art of persuasive selling.Join the elite ranks of P&C agents. Sign up for Agent Elite today and get exclusive resources to grow your agency!

In this exciting episode of The Insurance Dudes, join hosts Craig and Jason as they bring in the dynamic Jas Takhar live from his own studio. Known for his high-energy approach, Jas promises to match and potentially exceed the enthusiastic vibes. Dive into a lively conversation filled with rapid-fire questions and insightful discussions on content creation, real estate sales, and the impact of personal branding in business. Jas shares his journey from being labeled a little narcissistic to becoming a prolific content creator and successful real estate agent. Learn how building a personal media squad transformed his business and why staying true to your passion is key in any industry.Whether you're an insurance agent or a budding entrepreneur, this episode brims with actionable advice and motivational insights to revitalize your career and inspire your entrepreneurial spirit. Tune in and get ready for some high-energy exchanges and valuable takeaways from The Insurance Dudes and their engaging guest, Jas Takhar!Join the elite ranks of P&C agents. Sign up for Agent Elite today and get exclusive resources to grow your agency!

In this episode of The Insurance Dudes, join hosts Craig Pretzinger and Jason as they dive into an insightful conversation with Sales Coach and Speaker, Rob Liano. Growing up as the youngest of four boys with a father who transitioned from engineering to excelling in vacuum sales, Rob learned early on about the power of sales and determination. From his beginnings as a rock drummer to becoming a renowned sales trainer, Rob shares his journey of overcoming financial hardships and rediscovering the potential of sales as a career path.Discover the importance of customer-centric sales approaches, the necessity of continuous learning, and embracing technology to enhance business practices. This episode is filled with valuable lessons for sales professionals and entrepreneurs alike, making it a must-listen for those looking to elevate their sales strategies in 2021 and beyond.Join the elite ranks of P&C agents. Sign up for Agent Elite today and get exclusive resources to grow your agency!

In this episode of The Insurance Dudes, hosts Craig Pretzinger and Jason Feldman sit down with Wild Bill Rice to explore the ins and outs of lead generation within the insurance industry. As a seasoned professional in marketing and lead generation, Bill Rice offers valuable insights into understanding the unique challenges and opportunities tied to insurance leads. They delve into effective strategies for engaging potential clients, the importance of nurturing leads, and the role of persistence and adaptability in today's market.Whether you're a new agent looking to build your book of business or a seasoned pro seeking fresh perspectives, this episode is packed with actionable advice that can help you elevate your sales game. Join us as we discover the secrets to transforming leads into loyal customers, and learn how insurance agents can harness the power of effective marketing techniques to drive success in their agencies.Join the elite ranks of P&C agents. Sign up for Agent Elite today and get exclusive resources to grow your agency!

Got thoughts, feedback, or questions? We'd love to hear from you—send us an email.In this episode of The Art of Letting Go, I'm joined by my friend and collaborator DDM (aka Manny), a genre-defying artist who's built his own creative universe rooted in authenticity, boldness, and evolution. We talk about his journey from battle rap to redefining queer artistry in hip-hop, navigating identity, and what it means to measure success on your own terms.I also reflect on my return to the basketball court at a recent gay tournament, what it taught me about presence and self-acceptance, and why we have to meet ourselves where we are.This episode is for anyone learning to own their story—on the court, on the mic, and in life.

This week, Gilly is confronting her biggest summertime phobia with Tom Kerridge and his latest book, The Barbecue Book.He's the man with the Midas touch – he turned the Hand and Flowers from a rundown pub in Buckinghamshire into the first and only 2 star Michelin pub in the world. He's the chef who lost a stack of weight and turned his diet story into books and telly which helped millions of others do the same. He's the boy who grew up on free school meals who launched Full Time Meals with Marcus Rashford in 2021 and campaigns for free school meals for all children in the UK. He's the Michelin star chef whose books elevate the simplest of dishes. But is he the man who can teach Gilly how to love a barbie?Pop over to Gilly's Substack for Extra Bites Hosted on Acast. See acast.com/privacy for more information.

Episode 20In this podcast, professional astrologers Chani Nicholas, Thea Anderson, and Eliza Robertson look to the sky to make sense of what's happening here on Earth.This episode brings you into the astrological group chat to talk through how the Full Moon in Scorpio, the Uranus cazimi, and Jupiter's square to the lunar nodes have manifested IRL. We get into everything from the Democratic cover-up of Joe Biden's decline to the start of the Diddy trial, the fire at a 166-year-old plantation, and the selection of the new Pope — then we break down how these key astrological events have shown up in the collective. We also look ahead to Saturn's shift into Aries and unpack what that transit means for anyone entering a Saturn return, or any other significant Saturn transit. We rant. We reflect. We keep it real. There's a lot to get to, so let's get going.Content warning: sex trafficking, sexual assault, genocide, slavery, murder, wildfiresTimestamps:(00:00) - Welcome to Down to Astro episode 20(08:56) - Personal stories from the Scorpio Full Moon(15:00) - Political reflections: Joe Biden's Scorpio stellium(21:00) - The Diddy trial: uncovering dark secrets(26:56) - Cassie's case and the Mars Synodic Cycle(36:44) - Historical parallels: Anita Hill and Cassie(38:16) - Mars cazimi, 1991 and now: South Africa in the news(42:22) - The Full Moon and high-profile trials(44:48) - The importance of centering survivors(48:08) - Saturn, Ceres, and Cassie on the stand(50:42) -  Burning down the past: Neptune and the Nottoway Plantation fire(57:39) - The Scorpio Moon, the Mars–Pluto opposition, and global politics(01:07:39) - Power outages, tech failures, and the Uranus cazimi(01:14:04) - The significance of Jupiter's square to the nodes of the Moon(01:18:21) - Jupiter, ChatGPT, and the impact of tech in higher education(01:22:44) - The astrology of Pope Leo XIV(01:30:45) - Saturn's shift into Aries(01:37:40) - Navigating your second Saturn return(01:39:45) - Saturn squares: key Saturn transits in your 30s and 40s(01:41:09) - Upcoming astrological shifts: Saturn in Aries and Jupiter in CancerThis episode was recorded on 5/20/2025.For more astrological insights, download the CHANI app or follow CHANI on Instagram, TikTok, and Bluesky.The song “Midas,” featured in the podcast, was created by NISHA and is available wherever you listen to music.This episode also mentioned the following creative works:Original Sin: President Biden's Decline, Its Cover-Up, and His Disastrous Choice to Run Again by Jake Tapper and Alex ThompsonWe Do Not Care Club series on TikTok by @justbeingmelaniDoppelganger by Naomi KleinP.S. The transcript for this episode is available here.

They took the audience back in time to the 1940's with period costumes, a creative set design, and delightful music. On this episode of the Supercast, listen as Midas Creek Elementary School students take the stage in a lively and uplifting performance of the musical “Don't Say No to the USO.” It is a family-friendly ...continue reading "Episode 298: Midas Creek Elementary School Musical Takes Audience Back in Time"

The Daily Quiz - General Knowledge Today's Questions: Question 1: Which word is defined as 'in Turkey and some other Oriental countries, a decree or mandate issued by the sovereign'? Question 2: What grammatical unit can be simple, compound or complex? Question 3: What is the Spanish word for "thank you"? Question 4: What Native Language Would Jesus Christ Have Spoken? Question 5: What does the "touch of Midas" turn everything? Question 6: What do Karen, Richard and Joseph all have in common Question 7: Which word is defined as 'the symbol ÷'? Question 8: Which word is defined as 'copious but meaningless talk or writing'? Question 9: What does the Latin abbreviation term 'e.g.' mean? This podcast is produced by Klassic Studios Learn more about your ad choices. Visit megaphone.fm/adchoices

Brian Koziol is joined by Jeff Midas on the PGA Championship and the big swing of the leaderboard, Thurman Thomas on the NFL Schedule and James Cook, and Ryan Hasenauer to provide his picks for the Preakness

1. S.O.T.N & Tyron Hapi - Never Be Like You 2. ayokay & Oliver River - Heartbeat 3. DJ LEWIS, Midas the Jagaban - Get Down 4. ORIKO & KYPT - Water 5. Nu Aspect & Marlo Rex - Watching Over You 6. Atlantix - The One That Got Away 7. George.Alexander - Weak 8. Sam Silver, GROOVY & Cade Clair - Heart Attack 9. Gabi Sklar - Miami (Switch Disco Remix) 10. HILLS - Teardrops 11. KVSH & Future Skies - DNA 12. Luke Alexander & Notelle - Hypnotic 13. Dave Winnel - Neon Lights 14. Duke & Jones - Stush 15. Don Diablo - Freek Like Me 16. San Pacho - Go Getta (feat. Nevve) 17. Return Of The Jaded - Wattage In Your Cottage 18. Modapit - Don't Be Afraid 19. Karry G - Bando 20. The Temper Trap - Sweet Disposition (ARTBAT Remix)

The Daily Quiz - General Knowledge Today's Questions: Question 1: What does the "touch of Midas" turn everything? Question 2: Which word is defined as 'an interpreter or professional guide for travelers'? Question 3: What is the word for an auxiliary building near the main one? Question 4: What is another word for a prevarication? Question 5: Which word is defined as 'of, pertaining to, or resembling a hedgehog'? This podcast is produced by Klassic Studios Learn more about your ad choices. Visit megaphone.fm/adchoices

"Calcanhar de Aquiles", "Cavalo de Tróia", "Caixa de Pandora", "A sorte está lançada", "A César o que é de César", "Toque de Midas"... Estes são apenas alguns dos muitos ditados e expressões que têm suas origens na História Antiga. Mais do que apenas expressões sem grande valor, elas revelam o impacto duradouro das histórias e mitologias da antiguidade nas percepções humanas sobre o comportamento e os arquétipos humanos. Convidamos Vinicius Aleixo Fedel, historiador e apresentador do podcast Colunas de Hércules, para discutirmos as origens históricas e os significados de cada um deles.Dia das mães Insider! Use o cupom HISTORIAFM para 15% de desconto, ou acesse o site pelo link https://creators.insiderstore.com.br/HISTORIAFM #insiderstore

Acts 9:1-20; Psalm 30: Thanksgiving for Recovery from Grave Illness; John 21:1-19“On the Pulse of Morning” excerptHere, on the pulse of this fine dayYou may have the courageTo look up and out and upon me, theRock, the River, the Tree, your country.No less to Midas than the mendicant.No less to you now than the mastodon then.Here, on the pulse of this new dayYou may have the grace to look up and outAnd into your sister's eyes, and intoYour brother's face, your countryAnd say simplyVery simplyWith hope—Good morning.-Maya Angelou

Episode 19In this podcast, professional astrologers Chani Nicholas, Thea Anderson, and Eliza Robertson look to the sky to make sense of what's happening here on Earth.This episode brings you into the astrological group chat to talk about how the Mars–Pluto opposition and new Aries era have landed IRL. Covering everything from the Blue Origin flight to Beyoncé's birth chart reading, the passing of Pope Francis, and the impact of Sinners' success at the box office, we look back at how recent planetary power struggles manifested in the collective. Plus, we give a preview of what to expect when Saturn changes signs at the end of May. It's practical. It's fun. It's chatty. And it's the women x space collab you deserve.Content warning: Vancouver and New Orleans terror attacksTimestamps:(00:00) - Welcome to Down to Astro episode 19(03:06) - Previous Mars–Pluto predictions: revolution and struggles for power(05:51) - Venus and Neptune in Pisces: women in space(17:59) - Defying authority: the role of judges and the law(20:57) - Violence and tragedy: the Mars–Pluto opposition reflected in recent headlines(31:12) - The impact of Trump on the Canadian election(39:02) - The passing of Pope Francis and its astrological significance(46:17) - Economic turmoil and the role of Uranus(56:30) - The influence of Venus in Aries: the Met Gala(01:01:01) - Cowboy Carter and Beyoncé's astrology(01:11:20) - Sinners: 1932's nodal return reflected in cinema(01:20:50) - Ask us anything: the transition to Saturn in Aries(01:24:41) - Imagining a new reality with the upcoming Saturn–Neptune conjunctionThis episode was recorded on 04/29/2025.For more astrological insights, download the CHANI app or follow CHANI on Instagram, TikTok, and Bluesky.The song “Midas,” featured in the podcast, was created by NISHA and is available wherever you listen to music.This episode also mentioned the following creative works:“The Astrology Podcast” hosted by Chris Brennan“Cowboy Carter” by Beyoncé“Cowboy Carter Art Book” by BeyoncéThe New York Times/Siena SurveyP.S. The transcript for this episode is available here.

Join us for an insightful panel discussion sponsored for Bitlayer and live from Bitcoin Next at Eth Denver 2025 featuring industry titans, Josh Krieger from the Edge of Show, Romain Bourgois from Midas, Tobi Bauer from TB Ventures and Dan Held from Asymmetric Capital. In this episode, we dive deep into the evolving role of Bitcoin in institutional investment strategies, exploring the compelling reasons for institutions to consider Bitcoin as part of their portfolios.Key takeaways:The impact of institutional players like BlackRock and Fidelity on Bitcoin adoption.The significance of Bitcoin ETFs and their role in simplifying access for investors.The growing interest from family offices and traditional asset managers in Bitcoin and DeFi.The future of Bitcoin as a store of value and its potential integration with real-world assets.Challenges institutions face, including volatility and regulatory concerns.Whether you're a seasoned investor or new to the crypto space, this episode offers valuable insights into the future of Bitcoin and its place in the financial ecosystem. Don't forget to like, subscribe, and hit the notification bell for more content like this!Support us through our Sponsors! ☕